A retrospective study to explore the risk of HBV reactivation in patients with concomitant HBV infection who had received anti-CD19 CAR T therapy for relapsed or refractory B-cell lymphoma
Latest Information Update: 13 Dec 2019
At a glance
- Drugs Inaticabtagene autoleucel (Primary)
- Indications B-cell lymphoma
- Focus Adverse reactions
Most Recent Events
- 13 Dec 2019 New trial record
- 10 Dec 2019 Results presented at the 61st Annual Meeting and Exposition of the American Society of Hematology